AIA
SCMP

Affinity Investment Advisors’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Affinity Investment Advisors’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-24,165
Closed -$434K – 199
2017
Q4 		$434K Buy
24,165
+336
+1% +$4.14K 0.05% 107
2017
Q3 		$281K Buy
23,829
+1,630
+7% +$18.3K 0.03% 137
2017
Q2 		$233K Sell
22,199
-8,856
-29% -$90.3K 0.03% 151
2017
Q1 		$342K Buy
+31,055
New +$360K 0.03% 140

Other funds holding SCMP

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Affinity Investment Advisors's SCMP Position: Q1 2018 in Review

Affinity Investment Advisors sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 24,165 shares — an estimated $434K sold.

Affinity Investment Advisors first reported a position in SCMP in Q1 2017 and held it in 4 quarters. The position peaked at $434K in Q4 2017. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

  • Affinity Investment Advisors reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Affinity Investment Advisors sold 24,165 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $434K.
  • Affinity Investment Advisors first reported a position in Sucampo Pharmaceuticals, Inc. in Q1 2017 and held it in 4 quarters.
  • Affinity Investment Advisors's Sucampo Pharmaceuticals, Inc. position peaked at $434K in Q4 2017.
  • 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on Affinity Investment Advisors's 13F filing for Q1 2018, filed 8 May 2018.